Table of contents
- Trial overview
- Who was studied
- What the trials measured
- Trial design and phases
- Main study comparisons
- Safety endpoints
Trial overview
The source data describes three interventional studies that included INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT as part of influenza vaccine research.[1][2][3] Two studies were in Phase 2, and one study was in Phase 3.[1][2][3] The main condition studied was Influenza, Human, with one larger study also including healthy people and people with stable comorbidities that increase flu complication risk.[1][2][3]
Who was studied
One Phase 2 study included adults 18 years of age and older.[1] Another Phase 2 study also included adults 18 years and older.[2] The Phase 3 study focused on adults aged 50 years and older, including both healthy individuals and people with stable comorbidities.[3]
In simple terms, a comorbidity means another health problem that a person already has.[3] The Phase 3 study used this broader group because it wanted to understand vaccine response in older adults, including those at higher risk of flu problems.[3]
What the trials measured
The Phase 2 studies measured the body’s immune response by looking at antibody titer at Day 29, the fold increase from Day 1 to Day 29, seroconversion, and seroprotection.[1][2] These are blood-based measures that help show whether the study intervention caused the immune system to respond.[1][2]
The Phase 3 study measured immunogenicity, which means how strongly the vaccine-related intervention triggered an immune response.[3] It compared results across three lots and also compared the study vaccine approach with other influenza vaccine options using geometric mean titers and seroconversion rates.[3]
Trial design and phases
All three studies were interventional, meaning researchers gave study interventions and then measured the results.[1][2][3] The two Phase 2 studies were designed to assess immune response and safety in adults 18 years and older.[1][2] The Phase 3 study was larger and focused on lot-to-lot consistency and noninferiority comparisons in adults 50 years and older.[3]
Noninferiority means the new approach is being tested to see if it is not worse than the comparison approach by more than a set amount.[3] Lot-to-lot consistency means checking whether different production batches give similar immune responses.[3]
Main study comparisons
In the Phase 2 studies, the goal was to evaluate the humoral immune response, which is the part of the immune system that makes antibodies in the blood.[1][2] The studies also looked at safety and reactogenicity, meaning the expected short-term reactions after the study intervention.[1][2]
The Phase 3 study first compared three consecutive lots of aQIVc HD in pairs, then compared aQIVc HD against QIVr and aQIV for each vaccine strain.[3] The study used hemagglutination inhibition, or HI assay, which is a lab test used to measure antibodies against flu strains.[3]
The Phase 3 study included the strain INFLUENZA B VIRUS VICTORIA LINEAGE HAEMAGGLUTININ, RECOMBINANT among the four vaccine strains analyzed.[3] It also included comparisons using other influenza strains named in the source data, such as H1N1 and H3N2 components.[3]
Safety endpoints
The Phase 2 studies tracked solicited administration site or systemic events within 7 days, which means expected reactions at the injection site or in the whole body after the study intervention.[1][2] They also tracked unsolicited adverse events within 28 days, serious adverse events within 6 months, adverse events of special interest within 6 months, medically attended adverse events within 6 months, and laboratory abnormalities at several time points.[1][2]
These safety measures help researchers see whether the study intervention causes unexpected problems or changes in blood tests.[1][2] The Phase 3 study summary in the source data focuses mainly on immune response and lot consistency, while the Phase 2 studies give the clearest detailed safety endpoints.[1][2][3]
